INGELHEIM, Germany - Monday, December 5th 2016 [ME NewsWire]
New analysis of GLORIA™-AF Registry Program includes data from nearly 3,000 patients across the world1
Data presented at the American Society of Hematology (ASH) Annual Meeting1
(BUSINESS WIRE)-- Boehringer Ingelheim today announced results from a new analysis of the GLORIA™-AF Registry Program, which showed that newly diagnosed non-valvular atrial fibrillation (NVAF) patients treated with Pradaxa® (dabigatran etexilate) had a 76.6 percent probability of remaining on treatment at one year and a 69.2 percent probability at two years. The results were presented at the American Society of Hematology (ASH) Annual Meeting in San Diego, CA.1
“Patients with NVAF are at a five times greater risk for stroke, and the goal of anticoagulant therapy is to reduce this risk. It is critical for patients and physicians to understand the benefits of staying on prescribed treatment and the potential risks of discontinuing,” said Jonathan Halperin, M.D., the Robert and Harriet Heilbrunn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, study author and member of the GLORIA™-AF steering committee. “In general, nearly half of patients discontinue oral anticoagulant therapy after only a year, so it is promising to see high adherence rates with Pradaxa® in this new analysis from the GLORIA™-AF Registry.”
The analysis was based on real-world data from 2,937 Pradaxa® patients receiving care at nearly 1,000 sites in 44 countries. Eighty-eight percent of the patients were considered at high risk for stroke (i.e., CHA2DS2-VASc score of 2 or higher), and many patients experienced other health conditions in addition to NVAF, including hypertension (78.9%), diabetes (22.7%) and heart failure (24.9%).1
“These latest results from the GLORIA™-AF Registry show that the majority of Pradaxa® patients follow their treatment plan as prescribed by their physician. By understanding how medicines are used in the real world, as well as the reasons why some patients might discontinue treatment, we can assist the medical community in identifying ways to improve patient outcomes,” said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Pradaxa® is the only non-vitamin K antagonist oral anticoagulant with a specific reversal agent approved and widely available across the globe. This, combined with the vast body of data from real-world clinical practice, offers physicians, patients and carers added assurance in reducing stroke risk in NVAF patients.”
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
~ENDS~
Please click on the link below for ‘Notes to Editors and References’:
http://www.boehringer-ingelheim.com/press-release/high-adherence-rates-with-pradaxa-in-nvaf-patients
Contacts
Boehringer Ingelheim GmbH
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail: press@boehringer-ingelheim.com
Twitter: http://twitter.com/Boehringer
or
More information
www.boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/19172/en
New analysis of GLORIA™-AF Registry Program includes data from nearly 3,000 patients across the world1
Data presented at the American Society of Hematology (ASH) Annual Meeting1
(BUSINESS WIRE)-- Boehringer Ingelheim today announced results from a new analysis of the GLORIA™-AF Registry Program, which showed that newly diagnosed non-valvular atrial fibrillation (NVAF) patients treated with Pradaxa® (dabigatran etexilate) had a 76.6 percent probability of remaining on treatment at one year and a 69.2 percent probability at two years. The results were presented at the American Society of Hematology (ASH) Annual Meeting in San Diego, CA.1
“Patients with NVAF are at a five times greater risk for stroke, and the goal of anticoagulant therapy is to reduce this risk. It is critical for patients and physicians to understand the benefits of staying on prescribed treatment and the potential risks of discontinuing,” said Jonathan Halperin, M.D., the Robert and Harriet Heilbrunn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, study author and member of the GLORIA™-AF steering committee. “In general, nearly half of patients discontinue oral anticoagulant therapy after only a year, so it is promising to see high adherence rates with Pradaxa® in this new analysis from the GLORIA™-AF Registry.”
The analysis was based on real-world data from 2,937 Pradaxa® patients receiving care at nearly 1,000 sites in 44 countries. Eighty-eight percent of the patients were considered at high risk for stroke (i.e., CHA2DS2-VASc score of 2 or higher), and many patients experienced other health conditions in addition to NVAF, including hypertension (78.9%), diabetes (22.7%) and heart failure (24.9%).1
“These latest results from the GLORIA™-AF Registry show that the majority of Pradaxa® patients follow their treatment plan as prescribed by their physician. By understanding how medicines are used in the real world, as well as the reasons why some patients might discontinue treatment, we can assist the medical community in identifying ways to improve patient outcomes,” said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Pradaxa® is the only non-vitamin K antagonist oral anticoagulant with a specific reversal agent approved and widely available across the globe. This, combined with the vast body of data from real-world clinical practice, offers physicians, patients and carers added assurance in reducing stroke risk in NVAF patients.”
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
~ENDS~
Please click on the link below for ‘Notes to Editors and References’:
http://www.boehringer-ingelheim.com/press-release/high-adherence-rates-with-pradaxa-in-nvaf-patients
Contacts
Boehringer Ingelheim GmbH
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail: press@boehringer-ingelheim.com
Twitter: http://twitter.com/Boehringer
or
More information
www.boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/19172/en